CHA
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
revised:
17
08
2024
received:
13
06
2024
accepted:
08
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
9
10
2024
Statut:
aheadofprint
Résumé
We evaluated the effect of CHA Patients with AF who received EVT in 353 centers in Japan (2018-2020) were included. The outcomes were symptomatic intracerebral hemorrhage (sICH), in-hospital mortality, functional independence, and successful and complete reperfusion. The effects of CHA Of the 6984 patients, 780 (11.2%) used warfarin and 1168 (16.7%) used direct oral anticoagulants (DOACs) before EVT. Based on the CHA Prior DOAC use for patients with high- and selected intermediate-risk CHA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP20ek0210129
Organisme : Japan Agency for Medical Research and Development
ID : JP19ek0210088
Organisme : Japan Agency for Medical Research and Development
ID : JP20ek0210147
Organisme : Japan Agency for Medical Research and Development
ID : JP21ek0210147
Organisme : Japan Agency for Medical Research and Development
ID : JP22ek0210147
Organisme : Intramural Research Fund for Cardiovascular Diseases of National Cerebral and Cardiovascular Center
ID : 20-4-10
Organisme : the Japanese Ministry of Health, Labour and Welfare
ID : 19AC1003
Organisme : the Japanese Ministry of Health, Labour and Welfare
ID : 21FA1010
Organisme : the Japanese Ministry of Health, Labour and Welfare
ID : 22FA1015
Organisme : the Japanese Ministry of Health, Labour and Welfare
ID : 23FA1014
Organisme : the Japanese Ministry of Health, Labour and Welfare
ID : 24FA1015
Organisme : the Japanese Ministry of Health, Labour and Welfare
ID : 24FA1016
Organisme : the Japanese Ministry of Health, Labour and Welfare
ID : H28-Shinkin-Ippan-011
Organisme : Japan Society for the Promotion of Science
ID : 22H03191
Organisme : Japan Society for the Promotion of Science
ID : 18H02914
Organisme : Japan Society for the Promotion of Science
ID : 23K24450
Organisme : Japan Society for the Promotion of Science
ID : 25293314
Informations de copyright
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Hart RG, Pearce LA, Aguilar MI. Meta‐analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857‐867.
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024;149:1‐156.
Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation. 2017;135:208‐219.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio‐Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart Rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42:373‐498.
Anjum M, Ariansen I, Hjellvik V, et al. Stroke and bleeding risk in atrial fibrillation with CHA2DS2‐VASC risk score of one: the Norwegian AFNOR study. Eur Heart J. 2024;45:57‐66.
Østergaard L, Olesen JB, Petersen JK, et al. Arterial thromboembolism in patients with atrial fibrillation and CHA(2)DS(2)‐VASc 1: a Nationwide study. Circulation. 2024;149:764‐773.
Tu HT, Campbell BC, Meretoja A, et al. Pre‐stroke CHADS2 and CHA2DS2‐VASc scores are useful in stratifying three‐month outcomes in patients with and without atrial fibrillation. Cerebrovasc Dis. 2013;36:273‐280.
Ntaios G, Lip GY, Makaritsis K, et al. CHADS₂, CHA₂S₂DS₂‐VASc, and long‐term stroke outcome in patients without atrial fibrillation. Neurology. 2013;80:1009‐1017.
Toyoda K, Yoshimura S, Nakai M, et al. Twenty‐year change in severity and outcome of ischemic and hemorrhagic strokes. JAMA Neurol. 2022;79:61‐69.
Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and safety of non‐vitamin K antagonist Oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta‐analyses. Clin Ther. 2017;39:1456‐1478.e36.
Meinel TR, Branca M, De Marchis GM, et al. Prior anticoagulation in patients with ischemic stroke and atrial fibrillation. Ann Neurol. 2021;89:42‐53.
Jung YH, Kim YD, Kim J, et al. Initial stroke severity in patients with atrial fibrillation according to antithrombotic therapy before ischemic stroke. Stroke. 2020;51:2733‐2741.
Ren N, Ogata S, Kiyoshige E, et al. Associations between adherence to evidence‐based, stroke quality indicators and outcomes of acute reperfusion therapy. Stroke. 2022;53:3359‐3368.
Ren N, Nishimura A, Kurogi A, et al. Measuring quality of Care for Ischemic Stroke Treated with Acute Reperfusion Therapy in Japan—the close the gap‐stroke. Circ J. 2021;85:201‐209.
Hacke W, Kaste M, Fieschi C, et al. Randomised double‐blind placebo‐controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European‐Australasian acute stroke study investigators. Lancet. 1998;352:1245‐1251.
Chen JH, Hong CT, Chung CC, Kuan YC, Chan L. Safety and efficacy of endovascular thrombectomy in acute ischemic stroke treated with anticoagulants: a systematic review and meta‐analysis. Thromb J. 2022;20:35.
Mac Grory B, Holmes DN, Matsouaka RA, et al. Recent vitamin K antagonist use and intracranial hemorrhage after endovascular Thrombectomy for acute ischemic stroke. JAMA. 2023;329:2038‐2049.
Ramos‐Araque ME, Chavarria‐Miranda A, Gomez‐Vicente B, et al. Oral anticoagulation and risk of symptomatic hemorrhagic transformation in stroke patients treated with mechanical Thrombectomy: data from the Nordictus registry. Front Neurol. 2020;11:594251.
Meinel TR, Kniepert JU, Seiffge DJ, et al. Endovascular stroke treatment and risk of intracranial hemorrhage in anticoagulated patients. Stroke. 2020;51:892‐898.
Suda S, Abe A, Iguchi Y, et al. Safety of recanalization therapy in patients with acute ischemic stroke on direct oral anticoagulants: a sub‐analysis of PASTA registry study. J Neurol Sci. 2023;448:120639.
D'Anna L, Romoli M, Foschi M, et al. Outcomes of mechanical thrombectomy in orally anticoagulated patients with anterior circulation large vessel occlusion: a propensity‐matched analysis of the Imperial college Thrombectomy registry. J Neurol. 2023;270:5827‐5834.
Küpper C, Feil K, Wollenweber FA, et al. Endovascular stroke treatment in orally anticoagulated patients: an analysis from the German stroke registry‐endovascular treatment. J Neurol. 2021;268:1762‐1769.
Goldhoorn RB, van de Graaf RA, van Rees JM, et al. Endovascular treatment for acute ischemic stroke in patients on Oral anticoagulants: results from the MR CLEAN registry. Stroke. 2020;51:1781‐1789.
Uphaus T, Singer OC, Berkefeld J, et al. Safety of endovascular treatment in acute stroke patients taking oral anticoagulants. Int J Stroke. 2017;12:412‐415.
Seiffge DJ, Hooff RJ, Nolte CH, et al. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation. 2015;132:1261‐1269.
Lawrence MJ, Evans V, Whitley J, et al. The effects of apixaban on clot characteristics in atrial fibrillation: a novel pharmacodynamic biomarker. Pharmacol Res Perspect. 2022;10:e00937.
Li G, Wu G, Qin Z, Li H, Cheng X, Cai Y. Prognostic value of clot burden score in acute ischemic stroke after reperfusion therapies: a systematic review and meta‐analysis. J Stroke Cerebrovasc Dis. 2019;28:104293.
Wang C, Hang Y, Cao Y, et al. Association between prior anticoagulation and thrombus composition in mechanical Thrombectomy patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2022;31:106347.
Fereidoonnezhad B, Dwivedi A, Johnson S, McCarthy R, McGarry P. Blood clot fracture properties are dependent on red blood cell and fibrin content. Acta Biomater. 2021;127:213‐228.
Maekawa K, Shibata M, Nakajima H, et al. Erythrocyte‐rich thrombus is associated with reduced number of maneuvers and procedure time in patients with acute ischemic stroke undergoing mechanical Thrombectomy. Cerebrovasc Dis Extra. 2018;8:39‐49.
Zhang Y, Jiang M, Gao Y, et al. “No‐reflow” phenomenon in acute ischemic stroke. J Cereb Blood Flow Metab. 2024;44:19‐37.
Sperring CP, Savage WM, Argenziano MG, et al. No‐reflow post‐recanalization in acute ischemic stroke: mechanisms, measurements, and molecular markers. Stroke. 2023;54:2472‐2480.
Ipek G, Onuk T, Karatas MB, et al. CHA2DS2‐VASc score is a predictor of No‐reflow in patients with ST‐segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology. 2016;67:840‐845.
Hwang J, Chung JW, Lee MJ, et al. Implications of CHA2DS2‐VASc score in stroke patients with atrial fibrillation: an analysis of 938 Korean patients. Eur Neurol. 2017;77:307‐315.
Soo Y, Abrigo JM, Leung KT, et al. Risk of intracerebral haemorrhage in Chinese patients with atrial fibrillation on warfarin with cerebral microbleeds: the IPAAC‐warfarin study. J Neurol Neurosurg Psychiatry. 2019;90:428‐435.
Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy—pooled analysis of the Shinken database, J‐RHYTHM registry, and Fushimi AF registry. Circ J. 2015;79:432‐438.
Lyrer F, Zietz A, Seiffge DJ, et al. Atrial fibrillation detected before or after stroke: role of anticoagulation. Ann Neurol. 2023;94:43‐54.